Season 4 of Surfing The NASH Tsunami

S4-26 - Patient Advocate Focus on International #NASHDay 2023

S4-26 – Patient Advocate Focus on International #NASHDay 2023

The episode celebrates and reflects on International #NASHDay 2023 with a panel of patient advocates (Michael Betel, Gina Villiotti Madison and Marko Korenjak) and co-hosts Louise Campbell and Roger Green. Each speaks to what the day means to them and the group explores how the community is taking action to step up to a public health epidemic.

S4-25 - Exciting News! NICE Guidance Supports FibroScan Use Outside Secondary and Specialist Care in the UK

S4-25 – Exciting News! NICE Guidance Supports FibroScan Use Outside Secondary and Specialist Care in the UK

To kick off International #NASHDay 2023, Surfing NASH starts its ongoing coverage with an episode dedicated to a momentous and fitting announcement. William Alazawi and Vanessa Hebditch join Louise Campbell and Roger Green to celebrate and comment on evidence-based guidance on FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care in the UK.

S4-24.5 - INCBCN Review: Wrap-Up Comments and Moving Forward

S4-24.5 – INCBCN Review: Wrap-Up Comments and Moving Forward

Surfing NASH reviews the recently concluded 2023 Innovations in NAFLD Care Workshop with conference founders and directors, Jeff Lazarus and Jörn Schattenberg. This final conversation captures closing comments and thoughts on building the innovative program into the future.

S4-24.4 - INCBCN Day 2 Summary

S4-24.4 – INCBCN Day 2 Summary

Surfing NASH reviews the recently concluded 2023 Innovations in NAFLD Care Workshop with conference founders and directors, Jeff Lazarus and Jörn Schattenberg. This conversation looks into the second day of the conference and the impact that the FDA ADCOM on obeticholic acid has on all of these issues discussed.

S4-24.3 - Focus on Preventative Hepatology

S4-24.3 – Focus on Preventative Hepatology

Surfing NASH reviews the recently concluded 2023 Innovations in NAFLD Care Workshop with conference founders and directors, Jeff Lazarus and Jörn Schattenberg. This conversation takes a deeper dive into what constitutes ‘preventative hepatology.’ The group teases out multiple concepts of what this could or should look like.

S4-24.2 - INCBCN Review: NAFLD and Social Drinking

S4-24.2 – INCBCN Review: NAFLD and Social Drinking

Surfing NASH reviews the recently concluded 2023 Innovations in NAFLD Care Workshop with conference founders and directors, Jeff Lazarus and Jörn Schattenberg. This conversation considers alcohol consumption and its impact on NAFLD. Additionally, the group discusses applying FibroScan in different patient settings.

S4-24.1 - INCBCN Review: NASH-NITs Real-World-Evidence Summit

S4-24.1 – INCBCN Review: NASH-NITs Real-World-Evidence Summit

The opening conversation sets the stage for the 2023 Innovations in NAFLD Care Workshop held in Barcelona from 26-27 May, 2023. Conference founders and directors Jeff Lazarus and Jörn Schattenberg discuss this year’s goals of the event and facilitating the hands-on NASH-NITs Real-World-Evidence Summit.

S4-23.1 - Obeticholic Acid: Is the Juice Worth the Squeeze?

S4-23.1 – Obeticholic Acid: Is the Juice Worth the Squeeze?

Stephen Harrison speaks with Louise Campbell and Roger Green about challenges and opportunities in NASH drug development. This conversation features Stephen’s take on the recent outcome of the FDA ADCOM meeting for obeticholic acid (OCA) as a treatment for pre-cirrhotic fibrosis due to NASH.

S4-23 - Stephen Harrison on Challenges and Opportunities in NASH Drug Development

S4-23 – Stephen Harrison on Challenges and Opportunities in NASH Drug Development

Stephen Harrison speaks with Louise Campbell and Roger Green about challenges and opportunities in NASH drug development. The group dives deep into a range of topics including drugs with strong metabolic foundations, the state of histopathology, clinical trial design and screen fail rates, FDA ADCOM on obeticholic acid and much more.

S4-22 - PART 1: FDA ADCOM Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis Due to NASH

S4-22 – PART 1: FDA ADCOM Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis Due to NASH

Donna Cryer joins Jörn Schattenberg and Roger Green for a session which draws from raw reflections on the recent FDA Advisory Committee meeting and its outcome for obeticholic acid. The group remains focused on a critical message that looks down the path forward for the liver community and meeting patient needs. Stay tuned for more coverage as SurfingNASH continues to meet with other KOLs and stakeholders to discuss the event and its implications.

S4-20.6 - From the Vault: Discussing NITs and Final Thoughts on NAFLD Summit

S4-20.6 – From the Vault: Discussing NITs and Final Thoughts on NAFLD Summit

Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Roger Green, on-site from Dublin to review their thoughts and key takeaways immediately after the NAFLD Summit ended. In this conversation From the Vault, the group discusses NITs and what will change between now and when this conference convenes next year.

S4-20.5 - Harnessing the Strengths of the Patient Advocate Community

S4-20.5 – Harnessing the Strengths of the Patient Advocate Community

In an honest discussion with Donna Cryer, Surfing NASH explores the challenges of championing patient-centricity and the importance of allied health as many impending and important decisions come to a head for the NAFLD/NASH community. This final conversation elaborates on the myriad abilities possessed by the patient community which can be deployed to the fight against Fatty Liver diseases.

S4-20.3 - Generating and Promoting the Data to Demonstrate Patient Needs

S4-20.3 – Generating and Promoting the Data to Demonstrate Patient Needs

In an honest discussion with Donna Cryer, Surfing NASH explores the challenges of championing patient-centricity and the importance of allied health as many impending and important decisions come to a head for the NAFLD/NASH community. This conversation focuses around what’s required to recruit all stakeholders to recognize the reality of this disease for patients and their needs.

S4-20.2 - Listening to Both Sides: Allied Health for Patient Empowerment

S4-20.2 – Listening to Both Sides: Allied Health for Patient Empowerment

In an honest discussion with Donna Cryer, Surfing NASH explores the challenges of championing patient-centricity and the importance of allied health as many impending and important decisions come to a head for the NAFLD/NASH community. In this conversation, Louise Campbell expands on the critical role of nurses as advocates with the unique ability to bridge the patient-physician gaps.

S4-20.1 - Who is going to be the Larry Kramer of NASH?

S4-20.1 – Who is going to be the Larry Kramer of NASH?

In an honest discussion with Donna Cryer, Surfing NASH explores the challenges of championing patient-centricity and the importance of allied health as many impending and important decisions come to a head for the NAFLD/NASH community. This introductory conversation features an impactful statement from Donna on the gravity surrounding these milestone moments and why patient inputs should be held paramount.

S4-19.6 - From the Vault: REGENERATE Redux: Clearing The Finish Line?

S4-19.6 – From the Vault: REGENERATE Redux: Clearing The Finish Line?

Stephen Harrison leads the rest of the Surfers (Jörn Schattenberg, Louise Campbell and Roger Green), through a discussion of Intercept Pharmaceuticals’ July 7 press release on re-analysis of the REGENERATE trial evaluating obeticholic acid (OCA) for treating of NASH fibrosis. This conversation asks (and attempts to answer) whether the REGENERATE reanalysis is likely to succeed in getting the drug approved.

S4-19.5 - Teasing the Difference Between Patient Advocate Voice and Patient Advocate Vote

S4-19.5 – Teasing the Difference Between Patient Advocate Voice and Patient Advocate Vote

Patient advocates and friends of the podcast Mike Betel (Fatty Liver Alliance), Tony Villiotti (NASHkNOWledge) and Wayne Eskridge (Fatty Liver Foundation) join co-hosts Louise Campbell and Roger Green to share a range of impressions on a public comments session around the draft report released by the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH. In this final conversation, each describes the most important thing they would like ICER to learn before another NASH drug analysis.

S4-19.4 - Patient Advocates Describe the Reasoning Behind Their Testimonies

S4-19.4 – Patient Advocates Describe the Reasoning Behind Their Testimonies

Patient advocates and friends of the podcast Mike Betel (Fatty Liver Alliance), Tony Villiotti (NASHkNOWledge) and Wayne Eskridge (Fatty Liver Foundation) join co-hosts Louise Campbell and Roger Green to share a range of impressions on a public comments session around the draft report released by the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH. In this conversation, the panelists dive into why they shared their specific testimonies among other takeaways.

S4-19.2 - Patient Advocates React to the Word “Empathy”

S4-19.2 – Patient Advocates React to the Word “Empathy”

Patient advocates and friends of the podcast Mike Betel (Fatty Liver Alliance), Tony Villiotti (NASHkNOWledge) and Wayne Eskridge (Fatty Liver Foundation) join co-hosts Louise Campbell and Roger Green to share a range of impressions on a public comments session around the draft report released by the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH.

S4-19.1 - How Did the Patient Advocates Come to Offer Testimonies?

S4-19.1 – How Did the Patient Advocates Come to Offer Testimonies?

Patient advocates and friends of the podcast Mike Betel (Fatty Liver Alliance), Tony Villiotti (NASHkNOWledge) and Wayne Eskridge (Fatty Liver Foundation) join co-hosts Louise Campbell and Roger Green to share a range of impressions on a public comments session around the draft report released by the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH. This opening conversation reveals how each guest became involved in the process and offers a preview of their reactions to the experience.

S4-19 - Patient Advocate Panel Responds to ICER Draft Report on Resmetirom and Obeticholic Acid for NASH

S4-19 – Patient Advocate Panel Responds to ICER Draft Report on Resmetirom and Obeticholic Acid for NASH

Patient advocates and friends of the podcast Mike Betel (Fatty Liver Alliance), Tony Villiotti (NASHkNOWledge) and Wayne Eskridge (Fatty Liver Foundation) join co-hosts Louise Campbell and Roger Green to share a range of impressions on a public comments session regarding the draft report released by the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH.

S4-18.6 - From the Vault: Clinical Care Pathway: What Can Be Done Today?

S4-18.6 – From the Vault: Clinical Care Pathway: What Can Be Done Today?

Last author and leading endocrinology Fatty Liver Opinion Leader Ken Cusi joins co-author Stephen Harrison, Louise Campbell and Roger Green to discuss the recent Clinical Care Pathway published in Gastroenterology. This conversation From the Vault answers the question “What Can Be Done Today?” in terms of screening and patient management without approved drugs.

S4-18.2 - Risk Stratification and Identification of NAFLD/NASH Patients in the Endocrinology Setting

S4-18.2 – Risk Stratification and Identification of NAFLD/NASH Patients in the Endocrinology Setting

In continuing conversation around clinical care pathways and the complex of metabolic diseases, SurfingNASH explores the key relationship and interplay between endocrinology and hepatology. This conversation features Cyrielle Caussy alongside Surfers Jörn Schattenberg, Louise Campbell and Roger Green discussing why endocrinology clinics are a critical setting for early identification of patients with NAFLD and NASH.

S4-18.1 - Meeting Cyrielle Caussy at the Intersection of Endocrinology and Hepatology

S4-18.1 – Meeting Cyrielle Caussy at the Intersection of Endocrinology and Hepatology

In continuing conversation around clinical care pathways and the complex of metabolic diseases, SurfingNASH explores the key relationship and interplay between endocrinology and hepatology. Jörn Schattenberg, Louise Campbell and Roger Green are joined by Cyrielle Caussy to discuss interprofessional collaboration, education and awareness on Fatty Liver disease and early identification of at-risk populations.

S4-18 - Interplay of Endocrinology and Hepatology in Treatment and Knowledge Development

S4-18 – Interplay of Endocrinology and Hepatology in Treatment and Knowledge Development

As part of ongoing dialogue around clinical care pathways and the complex of metabolic diseases, SurfingNASH dedicates a session to focus on the key relationship and interplay between endocrinology and hepatology. Jörn Schattenberg, Louise Campbell and Roger Green are joined by Cyrielle Caussy to discuss interprofessional collaboration and education for early identification of at-risk populations.

S4-17.8 - Predictions for the Surfing NASH 6th Anniversary Special

S4-17.8 – Predictions for the Surfing NASH 6th Anniversary Special

The Surfing NASH 3rd Anniversary Special offers a look back at the history of the podcast and the future of Fatty Liver with the original ‘Big Band’ of Surfers Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green. In this final conversation the group summarizes their thoughts and suggests what will be discussed on the 6th Anniversary Special in 2026. At the end of the episode, there is a birthday surprise.

S4-17.7 - Discussing the Drug Development Landscape and Growing Community Education

S4-17.7 – Discussing the Drug Development Landscape and Growing Community Education

The Surfing NASH 3rd Anniversary Special offers a look back at the history of the podcast and the future of Fatty Liver with the original ‘Big Band’ of Surfers Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green. In this conversation the group continues to discuss the trajectory of liver science, drug development, driving education, clinical trials and more.

S4-17.6 - The Trajectory of Liver Science: How Far Have We Come?

S4-17.6 – The Trajectory of Liver Science: How Far Have We Come?

The Surfing NASH 3rd Anniversary Special offers a look back at the history of the podcast and the future of Fatty Liver with the original ‘Big Band’ of Surfers Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green. In this conversation the group dives into the tremendous progress being made in liver science and ultimately building a roadmap to therapy.

S4-17.5 - Surfer Throwbacks: Meeting the Co-Hosts for the First Time

S4-17.5 – Surfer Throwbacks: Meeting the Co-Hosts for the First Time

The Surfing NASH 3rd Anniversary Special offers a look back at the history of the podcast and the future of Fatty Liver with the original ‘Big Band’ of Surfers Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green. In this conversation the group shares recollections of their introductions to the podcast as we play throwback clips to their debut appearances.

S4-17.4 - Stephen Harrison on Improving Clinical Trial Enrollment and Reminiscing on the Podcast’s Early Days

S4-17.4 – Stephen Harrison on Improving Clinical Trial Enrollment and Reminiscing on the Podcast’s Early Days

The Surfing NASH 3rd Anniversary Special offers a look back at the history of the podcast and the future of Fatty Liver with the original ‘Big Band’ of Surfers Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green. In this conversation, Stephen shares his latest work and interests before the group listens and reacts to a clip of the original introduction featured on earlier episodes.

S4-16.3 - The Untapped Potential of the Liver Community

S4-16.3 – The Untapped Potential of the Liver Community

The Surfers explore elements of 2022 that have produced ripples in the pond of liver disease. Donna Cryer speaks to seeding investments in the global community and how these partnerships have made a measurable impact for the field.

S4-E16 - Stepping Up to International #NASHDay 2023

S4-E16 – Stepping Up to International #NASHDay 2023

As a momentous year for NASH unfolds, the Surfers (Donna Cryer, Pam Danagher, Jörn Schattenberg and Roger Green) preview #NASHDay 2023 and discuss what activities and energies are leading up to the event.

S4-15.4 - Final Takeaways from Liver Forum 14 and Reviewing the Published Slides

S4-15.4 – Final Takeaways from Liver Forum 14 and Reviewing the Published Slides

Co-hosts Jörn Schattenberg and Roger Green review the 2023 Liver Forum with Executive Director Veronica Miller and speakers Mazen Noureddin, Michelle Long and Jeff McIntyre. In this final conversation, the group shares takeaways from the published slides that they feel will be worth reviewing for those who couldn’t join the meeting live.

S4-15.3 - Session VIII: Stretch Exercise: New Look at Statistics

S4-15.3 – Session VIII: Stretch Exercise: New Look at Statistics

Co-hosts Jörn Schattenberg and Roger Green review the 2023 Liver Forum with Executive Director Veronica Miller and speakers Mazen Noureddin, Michelle Long and Jeff McIntyre. In this conversation, the group revisits a perspective-shifting session titled “A New Look at Statistics.”

S4-15.2 - Liver Forum 14: Panelists Select Sessions of Interest

S4-15.2 – Liver Forum 14: Panelists Select Sessions of Interest

Co-hosts Jörn Schattenberg and Roger Green review Liver Forum 14 with Executive Director Veronica Miller and speakers Mazen Noureddin, Michelle Long and Jeff McIntyre. For this conversation, each panelist picks a session that captured their interest and Mazen provides a flavor of his talk on Compensated Cirrhosis Risk Stratification.

S4-15.1 - What is The Liver Forum and Initial Impressions

S4-15.1 – What is The Liver Forum and Initial Impressions

Co-hosts Jörn Schattenberg and Roger Green review Liver Forum 14 with Executive Director Veronica Miller and speakers Mazen Noureddin, Michelle Long and Jeff McIntyre. In this conversation, Veronica recaps the aims of the Forum and each panelist shares their initial reactions around what makes the meeting special.

S4-15 - Review of Liver Forum 14

S4-15 – Review of Liver Forum 14

Co-hosts Jörn Schattenberg and Roger Green review the 2023 Liver Forum with Executive Director Veronica Miller. Joining the session are meeting speakers Mazen Noureddin, Michelle Long and Jeff McIntyre. The group highlights how the event embodies truly integrative thinking.

S4-14.3 - Drug Development News: Phase 3 Press Releases on the Horizon

S4-14.3 – Drug Development News: Phase 3 Press Releases on the Horizon

Co-hosts Jörn Schattenberg, Louise Campbell and Roger Green convene to discuss what’s happening for fatty liver so far in 2023 and moving into the second quarter. In this conversation, the group share thoughts around drug development and the possibility of new Phase 3 press releases on the imminent horizon. Co-hosts Jörn Schattenberg, Louise Campbell and Roger Green convene to discuss what’s happening for fatty liver so far in 2023 and moving into the second quarter. In this conversation, the group share thoughts around drug development and the possibility of new Phase 3 press releases on the imminent horizon.

S4-14.1 - Discussing the 3rd Annual Liver Connect Conference

S4-14.1 – Discussing the 3rd Annual Liver Connect Conference

Co-hosts Jörn Schattenberg, Louise Campbell and Roger Green convene to discuss what’s happening for fatty liver so far in 2023 and moving into the second quarter. In this conversation, Jörn describes his attendance at the 3rd Annual Liver Connect Conference in California.

S4-14 - Co-Host Roundtable on the Liver Connect Conference, FibroScan and Pathways, Therapeutic News and More

S4-14 – Co-Host Roundtable on the Liver Connect Conference, FibroScan and Pathways, Therapeutic News and More

This week, co-hosts Jörn Schattenberg, Louise Campbell and Roger Green discuss the 3rd Annual Liver Connect Conference, NICE approval process for FibroScan in primary care, updates in the therapeutic pipeline, pathways and the Surfing NASH 4th anniversary special. The session is fun and full of surprises – like a new metaphor from Roger to describe fatty liver disease.

S4-13.5 - INCBCN 2023: What Will Be Its Impact?

S4-13.5 – INCBCN 2023: What Will Be Its Impact?

Surfing NASH previews the 2023 Innovations in NAFLD Care Workshop with conference founders and directors, Jeff Lazarus and Jörn Schattenberg. This final conversation investigates what sort of impact the Workshop will have in the imminent future and the factors that will determine its success.

S4-13.4 - INCBCN 2023: Not Your Average Conference

S4-13.4 – INCBCN 2023: Not Your Average Conference

Surfing NASH previews the 2023 Innovations in NAFLD Care Workshop with conference founders and directors, Jeff Lazarus and Jörn Schattenberg. This conversation explores qualities which set the event apart from others and expands on its interactive emphasis.

S4-13.3 - Discussing the Day 2 Program of INCBCN in Barcelona

S4-13.3 – Discussing the Day 2 Program of INCBCN in Barcelona

Surfing NASH previews the 2023 Innovations in NAFLD Care Workshop with conference founders and directors, Jeff Lazarus and Jörn Schattenberg. This conversation introduces themes and sessions from Day 2 in Barcelona, including a debate on diet: can vegetarianism cure NAFLD?

S4-13.2 - Linking NAFLD and NASH to Cancer and Educating on Fatty Liver Screening

S4-13.2 – Linking NAFLD and NASH to Cancer and Educating on Fatty Liver Screening

Surfing NASH previews the 2023 Innovations in NAFLD Care Workshop with conference founders and directors, Jeff Lazarus and Jörn Schattenberg. This conversation continues to introduce themes and sessions from Day 1 in Barcelona on May 26. The group dives in-dept to the linkage between Fatty Liver and cancers, and the importance of early liver health screening for cancer prevention.

Subscribe for free. New podcasts Wednesday Evening / Thursday Morning.

Apple
Spotify
Google
Stitcher
Buzzsprout
YouTube
SoundCloud

Experience Nudge Learning! Interested in a new way of learning?